Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis

Pharmacological and genetic evidence support a role for an involvement of the dopamine D2-receptor (D2-R) in the pathophysiology of schizophrenia. Previous molecular imaging studies have suggested lower levels of D2-R in thalamus, but results are inconclusive. The objective of the present study was...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular psychiatry 2022-02, Vol.27 (2), p.1233-1240
Hauptverfasser: Plavén-Sigray, Pontus, Ikonen Victorsson, Pauliina, Santillo, Alexander, Matheson, Granville J., Lee, Maria, Collste, Karin, Fatouros-Bergman, Helena, Sellgren, Carl M., Erhardt, Sophie, Agartz, Ingrid, Halldin, Christer, Farde, Lars, Cervenka, Simon
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1240
container_issue 2
container_start_page 1233
container_title Molecular psychiatry
container_volume 27
creator Plavén-Sigray, Pontus
Ikonen Victorsson, Pauliina
Santillo, Alexander
Matheson, Granville J.
Lee, Maria
Collste, Karin
Fatouros-Bergman, Helena
Sellgren, Carl M.
Erhardt, Sophie
Agartz, Ingrid
Halldin, Christer
Farde, Lars
Cervenka, Simon
description Pharmacological and genetic evidence support a role for an involvement of the dopamine D2-receptor (D2-R) in the pathophysiology of schizophrenia. Previous molecular imaging studies have suggested lower levels of D2-R in thalamus, but results are inconclusive. The objective of the present study was to use improved methodology to compare D2-R density in whole thalamus and thalamic subregions between first-episode psychosis patients and healthy controls. Differences in thalamocortical connectivity was explored based on the D2-R results. 19 antipsychotic-naive first-episode psychosis patients and 19 age- and sex-matched healthy controls were examined using high-resolution Positron Emission Tomography (PET) and the high-affinity D2-R radioligand [ 11 C]FLB457. The main outcome was D2-R binding potential (BP ND ) in thalamus, and it was predicted that patients would have lower binding. Diffusion tensor imaging (DTI) was performed in a subgroup of 11 patients and 15 controls. D2-R binding in whole thalamus was lower in patients compared with controls (Cohen’s dz = −0.479, p  = 0.026, Bayes Factor (BF) > 4). Among subregions, lower BP ND was observed in the ROI representing thalamic connectivity to the frontal cortex (Cohen’s dz = −0.527, p  = 0.017, BF > 6). A meta-analysis, including the sample of this study, confirmed significantly lower thalamic D2-R availability in patients. Exploratory analyses suggested that patients had lower fractional anisotropy values compared with controls (Cohen’s d  = −0.692, p  = 0.036) in the inferior thalamic radiation. The findings support the hypothesis of a dysregulation of thalamic dopaminergic neurotransmission in schizophrenia, and it is hypothesized that this could underlie a disturbance of thalamocortical connectivity.
doi_str_mv 10.1038/s41380-021-01349-x
format Article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_457719</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2656977607</sourcerecordid><originalsourceid>FETCH-LOGICAL-c642t-9744e7a48eb1743e19cbd269ffb4f9d71a8bb69475818b4f7f72cbe8b08f47143</originalsourceid><addsrcrecordid>eNp9Uk1vFCEYnhiNrdU_4EFJvHgQhRkYwINJ0_qVbOKleiXAMLvUWRiB2Xb9H_5fme62WpN6IJD3-Xjh5amqpxi9xqjhbxLBDUcQ1Rgi3BABL-9Vh5iwFlLK-P1ybqiABHNyUD1K6RyhGaQPq4OGMCoKeFj9OlupQa2dAV0Yy-4tOK1htMaOOUSgNsoNSrvB5S1wHiSzcj_DuIrWO_UWKJDy1G1B8ED57Ma0NauQnYFeuY0Fo8rO-pzAhcsr0LuYMrSjS6Er2BU3uVSUXTFa26yg8mrYltrj6kGvhmSf7Pej6uuH92cnn-Diy8fPJ8cLaFpSZygYIZYpwq3GjDQWC6O7uhV9r0kvOoYV17oV5bEc81JiPauNtlwj3hOGSXNUwZ1vurDjpOUY3VrFrQzKyX3pezlZSShjWBT-4k7-MI1l6bJmQW-x1pw0kmiFJDG9kZrWWmpBlW36miOsi92rO-1O3bdjGeJSTpMkLSL1fNt3O3rhrm1nymijGm6pbiPereQybKRAlLSUF4PnOwMTXcrOSx-ikhhxWksuSDu3eLlvEcOPyaYs1y4ZOwzK2zAlWVPREtogOs_ixT_U8zDF8oGF1dJWMNYiVlj1dcuQUrT9zXUxknOK5S7FsqRYXqVYXhbRs78feiO5jm0hNPvBFcgvbfzT-z-2vwE86QIm</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2656977607</pqid></control><display><type>article</type><title>Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis</title><source>MEDLINE</source><source>NORA - Norwegian Open Research Archives</source><source>SpringerLink Journals</source><source>SWEPUB Freely available online</source><creator>Plavén-Sigray, Pontus ; Ikonen Victorsson, Pauliina ; Santillo, Alexander ; Matheson, Granville J. ; Lee, Maria ; Collste, Karin ; Fatouros-Bergman, Helena ; Sellgren, Carl M. ; Erhardt, Sophie ; Agartz, Ingrid ; Halldin, Christer ; Farde, Lars ; Cervenka, Simon</creator><creatorcontrib>Plavén-Sigray, Pontus ; Ikonen Victorsson, Pauliina ; Santillo, Alexander ; Matheson, Granville J. ; Lee, Maria ; Collste, Karin ; Fatouros-Bergman, Helena ; Sellgren, Carl M. ; Erhardt, Sophie ; Agartz, Ingrid ; Halldin, Christer ; Farde, Lars ; Cervenka, Simon</creatorcontrib><description>Pharmacological and genetic evidence support a role for an involvement of the dopamine D2-receptor (D2-R) in the pathophysiology of schizophrenia. Previous molecular imaging studies have suggested lower levels of D2-R in thalamus, but results are inconclusive. The objective of the present study was to use improved methodology to compare D2-R density in whole thalamus and thalamic subregions between first-episode psychosis patients and healthy controls. Differences in thalamocortical connectivity was explored based on the D2-R results. 19 antipsychotic-naive first-episode psychosis patients and 19 age- and sex-matched healthy controls were examined using high-resolution Positron Emission Tomography (PET) and the high-affinity D2-R radioligand [ 11 C]FLB457. The main outcome was D2-R binding potential (BP ND ) in thalamus, and it was predicted that patients would have lower binding. Diffusion tensor imaging (DTI) was performed in a subgroup of 11 patients and 15 controls. D2-R binding in whole thalamus was lower in patients compared with controls (Cohen’s dz = −0.479, p  = 0.026, Bayes Factor (BF) &gt; 4). Among subregions, lower BP ND was observed in the ROI representing thalamic connectivity to the frontal cortex (Cohen’s dz = −0.527, p  = 0.017, BF &gt; 6). A meta-analysis, including the sample of this study, confirmed significantly lower thalamic D2-R availability in patients. Exploratory analyses suggested that patients had lower fractional anisotropy values compared with controls (Cohen’s d  = −0.692, p  = 0.036) in the inferior thalamic radiation. The findings support the hypothesis of a dysregulation of thalamic dopaminergic neurotransmission in schizophrenia, and it is hypothesized that this could underlie a disturbance of thalamocortical connectivity.</description><identifier>ISSN: 1359-4184</identifier><identifier>ISSN: 1476-5578</identifier><identifier>EISSN: 1476-5578</identifier><identifier>DOI: 10.1038/s41380-021-01349-x</identifier><identifier>PMID: 34759359</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>59/57 ; 59/78 ; 631/45 ; 692/699/476/1799 ; Anisotropy ; Antipsychotic Agents - therapeutic use ; Antipsychotics ; Bayes Theorem ; Bayesian analysis ; Behavioral Sciences ; Biological Psychology ; Clinical Medicine ; Cortex (frontal) ; Diffusion Tensor Imaging ; Dopamine ; Dopamine - metabolism ; Dopamine D2 receptors ; Genetic analysis ; Humans ; Klinisk medicin ; Magnetic resonance imaging ; Medical and Health Sciences ; Medicin och hälsovetenskap ; Medicine ; Medicine &amp; Public Health ; Mental disorders ; Meta-analysis ; Neural networks ; Neuroimaging ; Neurologi ; Neurology ; Neurosciences ; Neurotransmission ; Pharmacotherapy ; Positron emission tomography ; Positron-Emission Tomography - methods ; Psychiatry ; Psychosis ; Psychotic Disorders - metabolism ; Psychotropic drugs ; Psykiatri ; Receptors, Dopamine D3 - metabolism ; Schizophrenia ; Schizophrenia - metabolism ; Thalamus ; Thalamus - metabolism</subject><ispartof>Molecular psychiatry, 2022-02, Vol.27 (2), p.1233-1240</ispartof><rights>The Author(s) 2021</rights><rights>2021. The Author(s).</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>info:eu-repo/semantics/openAccess</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c642t-9744e7a48eb1743e19cbd269ffb4f9d71a8bb69475818b4f7f72cbe8b08f47143</citedby><cites>FETCH-LOGICAL-c642t-9744e7a48eb1743e19cbd269ffb4f9d71a8bb69475818b4f7f72cbe8b08f47143</cites><orcidid>0000-0003-1297-0816 ; 0000-0003-4080-4030 ; 0000-0001-7359-5250 ; 0000-0001-8103-6977</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41380-021-01349-x$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41380-021-01349-x$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,550,776,780,881,26544,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34759359$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-460424$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttps://lup.lub.lu.se/record/fe1bb843-4ba0-4cfc-b52b-b95ae3f2801b$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:148029709$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Plavén-Sigray, Pontus</creatorcontrib><creatorcontrib>Ikonen Victorsson, Pauliina</creatorcontrib><creatorcontrib>Santillo, Alexander</creatorcontrib><creatorcontrib>Matheson, Granville J.</creatorcontrib><creatorcontrib>Lee, Maria</creatorcontrib><creatorcontrib>Collste, Karin</creatorcontrib><creatorcontrib>Fatouros-Bergman, Helena</creatorcontrib><creatorcontrib>Sellgren, Carl M.</creatorcontrib><creatorcontrib>Erhardt, Sophie</creatorcontrib><creatorcontrib>Agartz, Ingrid</creatorcontrib><creatorcontrib>Halldin, Christer</creatorcontrib><creatorcontrib>Farde, Lars</creatorcontrib><creatorcontrib>Cervenka, Simon</creatorcontrib><title>Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis</title><title>Molecular psychiatry</title><addtitle>Mol Psychiatry</addtitle><addtitle>Mol Psychiatry</addtitle><description>Pharmacological and genetic evidence support a role for an involvement of the dopamine D2-receptor (D2-R) in the pathophysiology of schizophrenia. Previous molecular imaging studies have suggested lower levels of D2-R in thalamus, but results are inconclusive. The objective of the present study was to use improved methodology to compare D2-R density in whole thalamus and thalamic subregions between first-episode psychosis patients and healthy controls. Differences in thalamocortical connectivity was explored based on the D2-R results. 19 antipsychotic-naive first-episode psychosis patients and 19 age- and sex-matched healthy controls were examined using high-resolution Positron Emission Tomography (PET) and the high-affinity D2-R radioligand [ 11 C]FLB457. The main outcome was D2-R binding potential (BP ND ) in thalamus, and it was predicted that patients would have lower binding. Diffusion tensor imaging (DTI) was performed in a subgroup of 11 patients and 15 controls. D2-R binding in whole thalamus was lower in patients compared with controls (Cohen’s dz = −0.479, p  = 0.026, Bayes Factor (BF) &gt; 4). Among subregions, lower BP ND was observed in the ROI representing thalamic connectivity to the frontal cortex (Cohen’s dz = −0.527, p  = 0.017, BF &gt; 6). A meta-analysis, including the sample of this study, confirmed significantly lower thalamic D2-R availability in patients. Exploratory analyses suggested that patients had lower fractional anisotropy values compared with controls (Cohen’s d  = −0.692, p  = 0.036) in the inferior thalamic radiation. The findings support the hypothesis of a dysregulation of thalamic dopaminergic neurotransmission in schizophrenia, and it is hypothesized that this could underlie a disturbance of thalamocortical connectivity.</description><subject>59/57</subject><subject>59/78</subject><subject>631/45</subject><subject>692/699/476/1799</subject><subject>Anisotropy</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotics</subject><subject>Bayes Theorem</subject><subject>Bayesian analysis</subject><subject>Behavioral Sciences</subject><subject>Biological Psychology</subject><subject>Clinical Medicine</subject><subject>Cortex (frontal)</subject><subject>Diffusion Tensor Imaging</subject><subject>Dopamine</subject><subject>Dopamine - metabolism</subject><subject>Dopamine D2 receptors</subject><subject>Genetic analysis</subject><subject>Humans</subject><subject>Klinisk medicin</subject><subject>Magnetic resonance imaging</subject><subject>Medical and Health Sciences</subject><subject>Medicin och hälsovetenskap</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Mental disorders</subject><subject>Meta-analysis</subject><subject>Neural networks</subject><subject>Neuroimaging</subject><subject>Neurologi</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Neurotransmission</subject><subject>Pharmacotherapy</subject><subject>Positron emission tomography</subject><subject>Positron-Emission Tomography - methods</subject><subject>Psychiatry</subject><subject>Psychosis</subject><subject>Psychotic Disorders - metabolism</subject><subject>Psychotropic drugs</subject><subject>Psykiatri</subject><subject>Receptors, Dopamine D3 - metabolism</subject><subject>Schizophrenia</subject><subject>Schizophrenia - metabolism</subject><subject>Thalamus</subject><subject>Thalamus - metabolism</subject><issn>1359-4184</issn><issn>1476-5578</issn><issn>1476-5578</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>3HK</sourceid><sourceid>D8T</sourceid><recordid>eNp9Uk1vFCEYnhiNrdU_4EFJvHgQhRkYwINJ0_qVbOKleiXAMLvUWRiB2Xb9H_5fme62WpN6IJD3-Xjh5amqpxi9xqjhbxLBDUcQ1Rgi3BABL-9Vh5iwFlLK-P1ybqiABHNyUD1K6RyhGaQPq4OGMCoKeFj9OlupQa2dAV0Yy-4tOK1htMaOOUSgNsoNSrvB5S1wHiSzcj_DuIrWO_UWKJDy1G1B8ED57Ma0NauQnYFeuY0Fo8rO-pzAhcsr0LuYMrSjS6Er2BU3uVSUXTFa26yg8mrYltrj6kGvhmSf7Pej6uuH92cnn-Diy8fPJ8cLaFpSZygYIZYpwq3GjDQWC6O7uhV9r0kvOoYV17oV5bEc81JiPauNtlwj3hOGSXNUwZ1vurDjpOUY3VrFrQzKyX3pezlZSShjWBT-4k7-MI1l6bJmQW-x1pw0kmiFJDG9kZrWWmpBlW36miOsi92rO-1O3bdjGeJSTpMkLSL1fNt3O3rhrm1nymijGm6pbiPereQybKRAlLSUF4PnOwMTXcrOSx-ikhhxWksuSDu3eLlvEcOPyaYs1y4ZOwzK2zAlWVPREtogOs_ixT_U8zDF8oGF1dJWMNYiVlj1dcuQUrT9zXUxknOK5S7FsqRYXqVYXhbRs78feiO5jm0hNPvBFcgvbfzT-z-2vwE86QIm</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>Plavén-Sigray, Pontus</creator><creator>Ikonen Victorsson, Pauliina</creator><creator>Santillo, Alexander</creator><creator>Matheson, Granville J.</creator><creator>Lee, Maria</creator><creator>Collste, Karin</creator><creator>Fatouros-Bergman, Helena</creator><creator>Sellgren, Carl M.</creator><creator>Erhardt, Sophie</creator><creator>Agartz, Ingrid</creator><creator>Halldin, Christer</creator><creator>Farde, Lars</creator><creator>Cervenka, Simon</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>3HK</scope><scope>5PM</scope><scope>ACNBI</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>DF2</scope><scope>ZZAVC</scope><scope>AGCHP</scope><scope>D95</scope><orcidid>https://orcid.org/0000-0003-1297-0816</orcidid><orcidid>https://orcid.org/0000-0003-4080-4030</orcidid><orcidid>https://orcid.org/0000-0001-7359-5250</orcidid><orcidid>https://orcid.org/0000-0001-8103-6977</orcidid></search><sort><creationdate>20220201</creationdate><title>Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis</title><author>Plavén-Sigray, Pontus ; Ikonen Victorsson, Pauliina ; Santillo, Alexander ; Matheson, Granville J. ; Lee, Maria ; Collste, Karin ; Fatouros-Bergman, Helena ; Sellgren, Carl M. ; Erhardt, Sophie ; Agartz, Ingrid ; Halldin, Christer ; Farde, Lars ; Cervenka, Simon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c642t-9744e7a48eb1743e19cbd269ffb4f9d71a8bb69475818b4f7f72cbe8b08f47143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>59/57</topic><topic>59/78</topic><topic>631/45</topic><topic>692/699/476/1799</topic><topic>Anisotropy</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotics</topic><topic>Bayes Theorem</topic><topic>Bayesian analysis</topic><topic>Behavioral Sciences</topic><topic>Biological Psychology</topic><topic>Clinical Medicine</topic><topic>Cortex (frontal)</topic><topic>Diffusion Tensor Imaging</topic><topic>Dopamine</topic><topic>Dopamine - metabolism</topic><topic>Dopamine D2 receptors</topic><topic>Genetic analysis</topic><topic>Humans</topic><topic>Klinisk medicin</topic><topic>Magnetic resonance imaging</topic><topic>Medical and Health Sciences</topic><topic>Medicin och hälsovetenskap</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Mental disorders</topic><topic>Meta-analysis</topic><topic>Neural networks</topic><topic>Neuroimaging</topic><topic>Neurologi</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Neurotransmission</topic><topic>Pharmacotherapy</topic><topic>Positron emission tomography</topic><topic>Positron-Emission Tomography - methods</topic><topic>Psychiatry</topic><topic>Psychosis</topic><topic>Psychotic Disorders - metabolism</topic><topic>Psychotropic drugs</topic><topic>Psykiatri</topic><topic>Receptors, Dopamine D3 - metabolism</topic><topic>Schizophrenia</topic><topic>Schizophrenia - metabolism</topic><topic>Thalamus</topic><topic>Thalamus - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Plavén-Sigray, Pontus</creatorcontrib><creatorcontrib>Ikonen Victorsson, Pauliina</creatorcontrib><creatorcontrib>Santillo, Alexander</creatorcontrib><creatorcontrib>Matheson, Granville J.</creatorcontrib><creatorcontrib>Lee, Maria</creatorcontrib><creatorcontrib>Collste, Karin</creatorcontrib><creatorcontrib>Fatouros-Bergman, Helena</creatorcontrib><creatorcontrib>Sellgren, Carl M.</creatorcontrib><creatorcontrib>Erhardt, Sophie</creatorcontrib><creatorcontrib>Agartz, Ingrid</creatorcontrib><creatorcontrib>Halldin, Christer</creatorcontrib><creatorcontrib>Farde, Lars</creatorcontrib><creatorcontrib>Cervenka, Simon</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>NORA - Norwegian Open Research Archives</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SWEPUB Uppsala universitet full text</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Uppsala universitet</collection><collection>SwePub Articles full text</collection><collection>SWEPUB Lunds universitet full text</collection><collection>SWEPUB Lunds universitet</collection><jtitle>Molecular psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Plavén-Sigray, Pontus</au><au>Ikonen Victorsson, Pauliina</au><au>Santillo, Alexander</au><au>Matheson, Granville J.</au><au>Lee, Maria</au><au>Collste, Karin</au><au>Fatouros-Bergman, Helena</au><au>Sellgren, Carl M.</au><au>Erhardt, Sophie</au><au>Agartz, Ingrid</au><au>Halldin, Christer</au><au>Farde, Lars</au><au>Cervenka, Simon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis</atitle><jtitle>Molecular psychiatry</jtitle><stitle>Mol Psychiatry</stitle><addtitle>Mol Psychiatry</addtitle><date>2022-02-01</date><risdate>2022</risdate><volume>27</volume><issue>2</issue><spage>1233</spage><epage>1240</epage><pages>1233-1240</pages><issn>1359-4184</issn><issn>1476-5578</issn><eissn>1476-5578</eissn><abstract>Pharmacological and genetic evidence support a role for an involvement of the dopamine D2-receptor (D2-R) in the pathophysiology of schizophrenia. Previous molecular imaging studies have suggested lower levels of D2-R in thalamus, but results are inconclusive. The objective of the present study was to use improved methodology to compare D2-R density in whole thalamus and thalamic subregions between first-episode psychosis patients and healthy controls. Differences in thalamocortical connectivity was explored based on the D2-R results. 19 antipsychotic-naive first-episode psychosis patients and 19 age- and sex-matched healthy controls were examined using high-resolution Positron Emission Tomography (PET) and the high-affinity D2-R radioligand [ 11 C]FLB457. The main outcome was D2-R binding potential (BP ND ) in thalamus, and it was predicted that patients would have lower binding. Diffusion tensor imaging (DTI) was performed in a subgroup of 11 patients and 15 controls. D2-R binding in whole thalamus was lower in patients compared with controls (Cohen’s dz = −0.479, p  = 0.026, Bayes Factor (BF) &gt; 4). Among subregions, lower BP ND was observed in the ROI representing thalamic connectivity to the frontal cortex (Cohen’s dz = −0.527, p  = 0.017, BF &gt; 6). A meta-analysis, including the sample of this study, confirmed significantly lower thalamic D2-R availability in patients. Exploratory analyses suggested that patients had lower fractional anisotropy values compared with controls (Cohen’s d  = −0.692, p  = 0.036) in the inferior thalamic radiation. The findings support the hypothesis of a dysregulation of thalamic dopaminergic neurotransmission in schizophrenia, and it is hypothesized that this could underlie a disturbance of thalamocortical connectivity.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>34759359</pmid><doi>10.1038/s41380-021-01349-x</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-1297-0816</orcidid><orcidid>https://orcid.org/0000-0003-4080-4030</orcidid><orcidid>https://orcid.org/0000-0001-7359-5250</orcidid><orcidid>https://orcid.org/0000-0001-8103-6977</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1359-4184
ispartof Molecular psychiatry, 2022-02, Vol.27 (2), p.1233-1240
issn 1359-4184
1476-5578
1476-5578
language eng
recordid cdi_swepub_primary_oai_swepub_ki_se_457719
source MEDLINE; NORA - Norwegian Open Research Archives; SpringerLink Journals; SWEPUB Freely available online
subjects 59/57
59/78
631/45
692/699/476/1799
Anisotropy
Antipsychotic Agents - therapeutic use
Antipsychotics
Bayes Theorem
Bayesian analysis
Behavioral Sciences
Biological Psychology
Clinical Medicine
Cortex (frontal)
Diffusion Tensor Imaging
Dopamine
Dopamine - metabolism
Dopamine D2 receptors
Genetic analysis
Humans
Klinisk medicin
Magnetic resonance imaging
Medical and Health Sciences
Medicin och hälsovetenskap
Medicine
Medicine & Public Health
Mental disorders
Meta-analysis
Neural networks
Neuroimaging
Neurologi
Neurology
Neurosciences
Neurotransmission
Pharmacotherapy
Positron emission tomography
Positron-Emission Tomography - methods
Psychiatry
Psychosis
Psychotic Disorders - metabolism
Psychotropic drugs
Psykiatri
Receptors, Dopamine D3 - metabolism
Schizophrenia
Schizophrenia - metabolism
Thalamus
Thalamus - metabolism
title Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T05%3A41%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thalamic%20dopamine%20D2-receptor%20availability%20in%20schizophrenia:%20a%20study%20on%20antipsychotic-naive%20patients%20with%20first-episode%20psychosis%20and%20a%20meta-analysis&rft.jtitle=Molecular%20psychiatry&rft.au=Plav%C3%A9n-Sigray,%20Pontus&rft.date=2022-02-01&rft.volume=27&rft.issue=2&rft.spage=1233&rft.epage=1240&rft.pages=1233-1240&rft.issn=1359-4184&rft.eissn=1476-5578&rft_id=info:doi/10.1038/s41380-021-01349-x&rft_dat=%3Cproquest_swepu%3E2656977607%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2656977607&rft_id=info:pmid/34759359&rfr_iscdi=true